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Abstract. Background. The differentiation of mild (F1-F2) and advanced fibrosis (F3-F4), as well as the ex-
clusion of fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), are extremely important for predic-
tion of the disease course. Integrative analyses of serum markers have been proposed as promising alternatives 
to biopsy method. Our study was targeted to develop a new model for determining the stage of fibrosis based 
on a more efficient combination of serological markers and to compare it with well-established algorithms. 
Materials and methods. Sixty patients with biopsy-proven NAFLD, including 26 (43 %) men and 34 (57 %) 
women, with average age of 37.10 ± 12.4 and 44.30 ± 7.25 years, respectively, were recruited for the study. 
Particularly, advanced fibrosis was diagnosed in 8 patients, 28 had mild fibrosis and 24 didn’t have any fibrosis 
according to morphological study. The following fibrosis markers were calculated: aspartate aminotransferase 
and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis 
index based on the 4 factor (FIB-4). Among many variables, hyaluronic acid, α
2
-macroglobulin, apolipopro-
tein A1, fibronectin, and haptoglobin were included in comprehensive study. Integrative model have been built 
up to determine the stage of fibrosis. The models were compared with the area under the receiver operating 
characteristic (AUROC) curves. Results. The ROC analysis showed that the FIB-4 demonstrated the largest 
AUROC, for the F2 — 0.72, F3 — 0.8, F4 — 0.82, respectively. Obtained results of the APRI were significantly 
higher for mild and advanced fibrosis (F2 — 0.74, F3 — 0.82). The AAR values were reliable only for liver cir-
rhosis (AUROC 0.89). A strong direct correlation was determined between the stage of fibrosis and the level of 
hyaluronic acid, α2-macroglobulin and fibronectin (r = 0.72, 0.93 and 0.71, p < 0.05, respectively). Whereas, 
we observed a moderate negative linear correlation between fibrosis stage and the indices of both apolipopro-
tein A1 and haptoglobin (r = –0.61; r = –0.35, respectively, p < 0.05). The positive correlation was determined 
between activity of the inflammatory process and the content of hyaluronic acid, α2-macroglobulin and fibro-
nectin (r = 0.54, 0.67 and 0.55 at p < 0.05), while the reverse moderate relation observed for apolipoprotein 
A1 and hapthoglobin (r = –0.56 and –0.33, p < 0.05). Conclusions. The analysis of obtained results showed 
that α2-macroglobulin, apolipoprotein A1, hyaluronic acid, and fibronectin had the greatest diagnostic validity 
among non-invasive markers of fibrosis. Every of them get the AUROC level higher than 0.75 for minimal fibrosis 
and, moreover, for moderate, significant fibrosis and cirrhosis they had an area more than 0.9.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most 
prevalent liver disease in the Western world and a common 
reason for clinical evaluation due to advance the liver func-
tion tests [1]. The histopathological features of NAFLD in-
clude a wide spectrum of changes, ranging from simple ste-
atosis to steatohepatitis and cirrhosis with risk of developing 
hepatocellular carcinoma [1]. Moreover, NAFLD has been 
established as a risk factor for cardiovascular morbidity and it 
is closely associated with an increased risk of metabolic dis-
ease, including diabetes [2]. Several follow-up studies have de-
monstrated increased mortality among patients with NAFLD. 
The main reason of the excess mortality belong to cardiovas-
cular diseases, however, liver-related mortality is also greatly 
overrepresented [3, 4]. There is no mutual consent on the 
item of the differences between NAFLD patients that need 
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the monitoring of early detection of future complications. 
However, hepatic fibrosis, particularly bridging fibrosis (stage 
3) or cirrhosis (stage 4) can be considered as the histological 
parameters that predict future risk of complications [5, 6]. 
Moreover, identification of NAFLD in patients with cirrho-
sis is critically important because screening for hepatocellular 
carcinoma and gastroesophageal varices is mandatory in these 
patients. Liver biopsy is the clinical reference standard to as-
sess the stage of fibrosis but this method has well documented 
problems as difficulties in samples obtaining, the interpreta-
tion variability as well as procedure related complications [7]. 
Liver biopsy is also expensive and it is characterized by low ac-
cess especially for general practitioners who take care of the 
majority of NAFLD patients. The limitations of liver biopsy 
have led to development of a variety of serum markers to iden-
tify the patients who have risk for clinically significant hepatic 
fibrosis. The most common approach to assess the stage of fi-
brosis by serological analysis requires the routine biochemical 
and/or hematological tests. These indirect serum markers are 
based on the evaluation of common functional alterations in 
the liver, the changes that do not necessarily reflect extracel-
lular matrix turnover and/or fibrogenic cell changes. A bet-
ter understanding of the liver fibrosis pathophysiology has 
prompted investigators to use more refined markers to iden-
tify differences in fibrosis stages. These, so called direct serum 
markers, are intended to detect extracellular matrix turnover 
and/or fibrogenic cell changes. Markers may be used alone 
or combined with other direct or indirect markers to form the 
panels. Several algorithms including a combination of indirect 
markers have been developed in NAFLD patients NAFLD fi-
brosis score [10], GUCI [12], APRI [13], FIB-4 [14], Forms 
score. It is unclear whether the algorithms that were devel-
oped in NAFLD patients provide a better diagnostic accu-
racy. The Enhanced Liver Fibrosis (ELF) test is an example 
of a panel of direct markers, which highlight matrix turnover 
and consists of tissue inhibitor of matrix metalloproteinase 1 
(TIMP 1), hyaluronic acid (HA), and aminoterminal peptide 
of pro-collagen III (P3NP) developed for a variety of liver dis-
orders [18]. Although the ELF panel has been reported to have 
a good diagnostic accuracy in NAFLD patients, the addition 
of indirect markers augments its diagnostic performance [19]. 
Other researchers have reported that one direct marker (HA) 
in combination with several indirect markers provides the best 
estimation of area of fibrosis measured with quantitative image 
analysis [11]. 
The purpose of our study was to assess the accuracy of 
non-invasive fibrosis algorithms to distinguish advanced 
fibrosis in NAFLD. Algorithms originally developed in 
NAFLD patients as well as in other liver diseases were com-
pared. Moreover, we aimed to develop a new non-invasive 
model for predicting advanced fibrosis in NAFLD and to 
compare its diagnostic accuracy with well established fibro-
sis algorithms.
Materials and methods
The study included patients with NAFLD who under-
went examination and treatment in SI “Institute of Gas-
troenterology of National Academy of Medical Sciences 
of Ukraine”. The study involved 60 patients with NAFLD, 
including 26 (43 %) men and 34 (57 %) women, average 
age of the patients was (37.1 ± 12.4) and (44.30 ± 7.25) re-
spectively. Every patient underwent physical examination, 
ultrasonography of the liver, laboratory investigation, and 
liver biopsy as part of the clinical work-up. Medical history 
was scrutinized as well as information regarding alcohol 
consumption. Blood pressure, waist circumference, body 
weight, and height were measured. Blood analysis for rou-
tine clinical biochemical analyses were performed at the 
local laboratories. These analyses included complete blood 
count and analysis of prothrombin time, alanine amino-
transferase (ALT), aspartate aminotransferase (AST), al-
kaline phosphatase (ALP), gamma glutamyl transferase 
(GGT), bilirubin, fasting plasma glucose, total cholesterol, 
high-density lipoprotein, low-density lipoprotein, trigly-
cerides. Moreover, serum samples were analyzed for levels 
of hyaluronic acid, α2-macroglobulin, apolipoprotein A1, 
fibronectin, and haptoglobin. Diagnosis of NAFLD was 
based on presence of hepatic steatosis at histopathologi-
cal evaluation without evidence of alcohol consumption 
> 140 g/week, any other concomitant liver disease, or medi-
cation associated with fatty infiltration of the liver.
Liver biopsy and histopathological evaluation. A percuta-
neous liver biopsy was performed using a 16 gauge (1.6 mm) 
needle. The median (range) biopsy length was 20 mm 
Table 1 — Modified classification according Brunt Necroinflammatory activity grades
A — Necroinflammatory activity grades
Grade Ballooning Lobular inflammation Portal inflammation
Grade 1 Occasional in zone 3 Polymorphous and mononuclear nuclei Mild and 
Diffuse
Absent or mild
Grade 2 Obvious in zone 3 Polymorphous nuclei associated with ballooning 
± and mononuclear nuclei
Absent, mild or moderate
Grade 3 Marcado in zone 3 Polymorphous nuclei concentrated in areas of 
ballooning. More inflammation than in grade 2
Mild or moderate, but not 
severe
B — Fibrosis stages
Stage 1 Pericellular fibrosis in zone 3 (focal or extensive)
Stage 2 Pericellular fibrosis in zone 3 (focal or extensive) plus portal fibrosis (focal or extensive)
Stage 3 Bridging fibrosis (focal or extensive)
Stage 4 Cirrhosis, ± residual pericellular fibrosis
Note. With permission of E.M. Brunt (106).
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Figure 1 — A — Liver biopsy specimen of the patient A. with F1 fibrosis; B — Liver biopsy specimen of the 
patient B. with F2 fibrosis F2; C — Liver biopsy specimen of the patient G. with F3 fibrosis; D — Liver biopsy 




(12 ± 32) mm. Biopsies were graded and staged according to 
the Brunt classification. 
In the morphological study, the absence of fibrosis was 
found in 24 (40 %) patients, mild fibrosis (F1) occurred 
in 23 (38.3 %), moderate (F2) — 5 (8.3 %), severe (F3) — 
4 (6.7 %), cirrhosis (F4) was detected in 4 (6.7 %) patients. 
Non-invasive fibrosis algorithms. For each patient, the 
AST/ALT (AAR) ratio was determined. The APRI and 
FIB-4 indices were calculated as follows:
FIB-4 = (age (years) × 
× AST (U/L))/(platelet count (G/L) × √ALT (U/L)).
APRI = (AST (U/L) × 100)/(AST (ULN) × 
× platelet count (G/L)).
All relevant primary patient-level data are shown in table 2.
Statistical analysis. Statistical analyses were per-
formed using SPSS (Statistica for Windows 10.0.) unless 
otherwise specified. The Shapiro-Wilk test was used to 
test for normal distribution. Median (range) was calcu-
lated for continuous variables, frequencies for categorical 
variables. Continuous variables were compared using the 
Student’s t test or the Mann — Whitney U test when ap-
propriate. The χ2 test or Fischer’s exact test were used to 
compare categorical variables. A two-sided p-value < 0.05 
was considered statistically significant if not specified oth-
erwise. Receiver-operating characteristics (ROC) curves 
of the tested scores were constructed for each stage of fi-
brosis as well as the area under the ROC curve (AUROC) 
was calculated to assess the overall diagnostic accuracy of 
serum fibrosis algorithms and to identify optimal cutoffs. 
The sensitivity, specificity were calculated according to 
standard methods.
Results
60 patients with NAFLD were examined (26 (42.3 %) 
male and 34 (56.7 %) female), the average age of the subjects 
was (37.1 ± 12.4) and (44.3 ± 7.3) years in accordance. An-
thropometric data of patients are presented in table 3.
The ROC analysis showed that FIB-4 index had the 
largest AUROC level for F 2 — 0.72, F3 — 0.8, F4 — 0.82, 
p < 0.05. We revealed APRI index was significantly higher 
for moderate and severe fibrosis (F2 — 0.74, F3 — 0.82, 
p < 0.05). And the AAR values were reliable only for liver 
cirrhosis (AUROC 0.89, p < 0.05).
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Table 2 — Laboratory and non-invasive test data
Parameter
Fibrosis stages
F0 F1 F2 F3 F4
n = 24 n = 23 n = 5 n = 4 n = 4
ALT, U/L 67.7 ± 77.5 54.8 ± 35.1 109.2 ± 111.1 94.9 ± 65.4 66.8 ± 52.1
AST, U/L 42.7 ± 47.8 35.3 ± 16.2 53.0 ± 36.9 56.0 ± 13.0 90.7 ± 76.1
Hyaluronic acid, g/l 1.14 ± 0.30 1.49 ± 0.35 1.81 ± 0.19 1.88 ± 0.04 2.03 ± 0.34
Apolipoprotein A1, g/l 1.91 ± 0.22 1.79 ± 0.24 1.33 ± 0.32 1.09 ± 0.05 0.98 ± 0.08
α
2
-macroglobulin, g/l 1.48 ± 0.15 1.99 ± 0.10 2.57 ± 0.18 2.87 ± 0.07 3.48 ± 0.41
Haptoglobin, g/l 1.22 ± 0.42 1.12 ± 0.28 0.998 ± 0.12 0.93 ± 0.14 0.14 ± 0.03
Fibronectin, g/l 0.27 ± 0.03 0.30 ± 0.03 0.35 ± 0.02 0.37 ± 0.08 0.45 ± 0.02
Protein-bound oxyproline, µmol/l 203.3 ± 50.3 229.3 ± 65.0 231.95 ± 28.95 219.3 ± 67.7 197.0 ± 109.3
FIB-4 0.82 ± 0.52 0.79 ± 0.35 0.80 ± 0.35 1.05 ± 0.28 1.46 ± 0.66
APRI 0.40 ± 0.43 0.32 ± 0.14 0.45±0.30 0.70±0.34 0.84 ± 0.53
AAR 0.76 ± 0.25 0.74 ± 0.24 0.62±0.21 0.74±0.31 1.32 ± 0.65
Table 3 — Anthropometric data of patients
Gender Weight, kg BMI, kg/m2
Men 91.4 ± 12.9 28.2 ± 3.6
Women 84.4 ± 12.7 29.0 ± 4.5




F1 F2 F3 F4
AAR
sensitivity, % 79.2 48.9 80.7 80.4
specificity, % 38.9 76.9 62.5 100
AUC 0.51 0.56 0.7 0.89
p 0.45 0.3 0.08 0.008
APRI
sensitivity, % 95.8 91.5 90.4 91.1
specificity, % 27.8 53.8 75 75
AUC 0.58 0.74 0.82 0.77
p 0.24 0.02 0.007 0.06
FIB-4
sensitivity, % 50 63.8 61.5 51.1
specificity, % 75 84,6 100 100
AUC 0.59 0.72 0.8 0.82
p 0.21 0.031 0.01 0.03
The data of the ROC analysis, depending on the stage 
of fibrosis, as well as the reliability of the differences in the 
indicators between the groups are shown in table 4.
Correlation analysis showed a strong direct correlation 
between the stage of fibrosis and the level of hyaluronic 
acid, α
2
-macroglobulin and fibronectin (r = 0.72, 0.93 
and 0.71 at p < 0.05 for Spearman correlation, respective-
ly). The moderate negative linear correlation (r = –0.61 
and –0.35, respectively, p < 0.05 for Spearman correla-
tion) was found between the indices of apolipoprotein A1, 
hapthoglobin and the fibrosis stage. We determined mo-
dreate positive corellation between the degree of inflam-
matory process acrivity and the indices of hyaluronic acid, 
α
2
-macroglobulin and fibronectin (r = 0.54, 0.67 and 0.55, 
respectively, p < 0.05 for the Spearman correlation) and 
the inverse corellation for apolipoprotein A1 and hapto-
globin (r = –0.56 and –0.33, respectively, p < 0.05 for the 
Spearman correlation). 
To determine the diagnostic value of the investigated se-
rum markers of fibrosis, an ROC analysis was performed, 
which resulted in a high sensitivity of the protein-bound 
oxyproline for fibroblastic stages from F2 to F4 and suffi-
cient sensitivity for minimal fibrosis and cirrhosis of the liver 
(75 %). The largest AUROC level (0.699, CI 0.466–0.931; 
the optimal threshold — 167) was observed in a case of liver 
cirrhosis. But these results were not statistically significant 
(p > 0,05). On the contrary, the sensitivity and specificity of 
hyaluronic acid for F3 fibrosis were statistically significant 
(p < 0.005), and had the largest AUROC level (0.915, CI 
0.837–0.992; the optimal threshold — 1.82).
The analysis of the results on the apolipoprotein A1 indi-
ces showed the largest AUROC level (0.997, CI 0.987–1.0; 
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the optimal threshold — 1.13) was established for severe 
fibrosis (F3). The sensitivity of the method for all fibrosis 
stages was quite high (96.4–100 %), but the specificity for 
minimal fibrosis (F1) was low (38.9 %).
The determining of α
2
-macroglobulin was almost the 
ideal method in our study, for which AUROC level reached 1 
for fibroblasts from F2 to F 4 with the optimum threshold — 
2.17 for F2, 2.75 — for F3 and 2.96 — for F4.
Concerning haptoglobin, high level of specificity was 
determined in the case of F1 and F2 (94.4 and 100 % re-
spectively) and had a rather low sensitivity level (33.0 and 
40.4 % respectively) in patients with minimal fibrosis and 
was not statistically significant. The largest AUROC level 
(1; CI 1–1; the optimal threshold — 0.67) was defined for 
liver cirrhosis (F4).
The fibronectin indices with a high level of sensitivity 
and specificity at all stages of fibrosis were statistically signi-
ficant. The largest AUROC level (curve) (0,996, CI 0.981–
1.01; the optimal threshold — 0.411) was defined for liver 
cirrhosis (F4).
Consequently, based on the data of non-invasive fibro-
sis markers in patients with NAFLD, the highest diagnostic 
value was shown for α
2
-macroglobulin, apolipoprotein A1, 
hyaluronic acid and fibronectin, for which the AUROC le-
vel for minimal fibrosis was higher than 0.75, and for moder-
ate, severe fibrosis and cirrhosis was more than 0.9.
Based on presented results and correlation analysis data, 
as well as the sensitivity and specificity of non-invasive mar-
kers, a model for diagnosing liver fibrosis was developed. The 
linear regression analysis was used for validation of the model.
The model of multiple linear regression for the indicator 
of the stage of liver fibrosis in patients with NAFLD had the 
following form:
Y = –2.0323 – 0.0011 × Х1 + 0.1173 × Х2 – 0.3090 × Х3 + 
+ 1.5905 × Х4 + 0.0283 × Х5 + 1.44 × Х6,
where Y — stage of fibrosis; X1 — the level of oxypro-
line protein-bound, X2 — the level of hyaluronic acid, 
X3 — the level of apolipoprotein A1, X4 — the level of α
2
-
macroglobulin, Х5 — the level of haptoglobin, X6 — the 
level of fibronectin.
Discussion
According to the results of our study, APRI was the most 
sensitive of the calculated indices, but its sensitivity was suf-
ficient only with developed fibrosis (F3–4). These data cor-
respond with foreign studies.
Recent study of F.C. Kruger et al. [34], presented compara-
tive analysis of the sensitivity and specificity of APRI, NFS and 
the ratio of ALT/AST. The analysis showed that for the diag-
nosis of severe fibrosis, APRI was more accurate than NFS 
and ALT/AST. Indicators of NFS in steatohepatitis were sig-
nificantly lower in the group with severe fibrosis. Positive prog-
nostic value for APRI was 54 %, while for NFS it was 34 %. 
Negative predictive value was 93 % for APRI and 94 % for NFS.
Study of Chinese researchers [35] included 131 patients, 
41 (31.3 %), 20 (15.3 %) and 10 (7.6 %) of patients had 
moderate fibrosis, severe fibrosis and cirrhosis, respectively. 
The highest accuracy of APRI with severe fibrosis (AUROC 
0.77) and liver cirrhosis (AUROC 0.86) was observed.
The results of our study of serum liver fibrosis markers 
showed the high correlation several of them with the stage 
of fibrosis and the degree of inflammation activity. Using 
a combination of these indicators can greatly improve the 
diagnosis of NAFLD. Thus, according to data of Indian 
researchers, [36] it was found the presence of strong posi-
tive correlation between the platelet count, gamma-gluta-
myltranspeptidase and apolipoprotein A and the absence of 
liver fibrosis in patients with NAFLD (negative predictive 
value — 94.3 %). The results of study Sakugawa and coau-
thors, showed that level of hyaluronic acid can be used to 
reliably distinguish the initial (F0–2) and severe fibrosis 
(F3–4) (AUC = 0.97) [37]. Kaneda et al. [38] determined 
that hyaluronic acid was independent of prognostic factors 
of severe fibrosis (F3–4) (AUC = 0.97).
Conclusions
Consequently, the results of the study indicate a high di-
agnostic accuracy of the combination of serum markers for 
the diagnosis of both fibrosis and its stage in patients with 
NAFLD. A few intuition, accessibility and the possibility to 
control these markers will allow developing more effective 
treatment tactics and screening for the dynamics changes in 
this category of patients.
The characterized markers may be useful in primary care 
to «rule out» NAFLD patients with advanced fibrosis that 
should be referred for monitoring of liver-related compli-
cations. In secondary care they may be useful to «rule in» 
NAFLD patients with advanced fibrosis thereby reducing 
need for liver biopsies. However, our results lack external 
validation and need to be evaluated in future studies.
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Степанов Ю.М., Недзвецька Н.В., Ягмур В.Б., Кленіна І.А., Ошмянська Н.Ю.
ДУ «Інститут гастроентерології НАМН України», м. Дніпро, Україна
Розробка неінвазивної моделі для підвищення точності діагностики 
стадії фіброзу печінки при неалкогольній жировій хворобі печінки
Резюме. Актуальність. Відмінність між м’яким (F1–2) 
і розвинутим фіброзом (F3–4), як і відсутність фібро-
зу у хворих на неалкогольну жирову хворобу печінки 
(НАЖХП), є важливим питанням для з’ясування прогнозу. 
Сироваткові маркери були запропоновані як альтернатива 
біопсії. Мета: розробити нову модель для визначення ста-
дії фіброзу на основі більш ефективної комбінації серо-
логічних маркерів та порівняння її з встановленими алго-
ритмами. Матеріали та методи. У дослідження включені 
60 пацієнтів із НАЖХП, які проходили обстеження і ліку-
вання у відділенні захворювань печінки та підшлункової 
залози ДУ «Інститут гастроентерології НАМН України». 
Серед досліджених 26 (42,3 %) чоловіків та 34 (56,7 %) 
жінки, середній вік яких (37,1 ± 12,4) та (44,3 ± 7,3) року 
відповідно. Всім пацієнтам була проведена черезшкірна 
пункційна трепан-біопсія печінки з подальшим морфо-
логічним дослідженням пунктату; виконано визначення 
вмісту гіалуронової кислоти, α
2
-макроглобуліну, аполіпо-
протеїну А1, фібронектину, гаптоглобіну в сироватці крові 
та був проведений розрахунок неінвазивних маркерів фі-
брозу печінки: AAR, APRI, FIB-4. Результати. Проведе-
ний ROC-аналіз показав, що найбільші показники площі 
під AUROC-кривою були для індексу FIB-4 для F2 — 0,72, 
F3 — 0,8, F4 — 0,82 при р < 0,05. Результати індексу APRI 
були вірогідно високими для помірного та виражено-
го фіброзу (F2 — 0,74, F3 — 0,82, р < 0,05). А показники 
AAR були вірогідними лише для цирозу печінки (площа 
під AUROC-кривою 0,89, р < 0,05). Установлено сильний 
прямий зв’язок між стадією фіброзу та рівнем гіалуроно-
вої кислоти, α
2
-макроглобуліну і фібронектину (r = 0,72, 
0,93 та 0,71 відповідно при р < 0,05) та обернений зв’язок 
помірної сили між показниками аполіпопротеїну А1, 
гаптоглобіну (r = –0,61 і –0,35 при р < 0,05). Визначено 
прямий зв’язок помірної сили між ступенем активності 
запального процесу і показниками гіалуронової кислоти, 
α
2
-макроглобуліну і фібронектину (r = 0,54, 0,67 та 0,55 
при р < 0,05) і обернений помірний зв’язок — аполіпопро-
теїну А1 та гаптоглобіну (r = –0,56 і –0,33 при р < 0,05). 
Висновки. Установлено, що найбільшу діагностичну цін-
ність із неінвазивних маркерів фіброзу мають показни-
ки α
2
-макроглобуліну, аполіпопротеїну А1, гіалуронової 
кислоти та фібронектину, для яких площа під AUROC-
кривою для мінімального фіброзу не була нижчою ніж 
0,75, а для помірного, вираженого фіброзу та цирозу ста-
новила більше 0,9.
Ключові слова: неалкогольна жирова хвороба печінки; фі-
броз печінки; біопсія печінки; неінвазивні методи діагнос-
тики
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Разработка неинвазивной модели для повышения точности диагностики 
стадии фиброза печени при неалкогольной жировой болезни печени
Резюме. Актуальность. Отличие между мягким (F1–2) 
и развитым фиброзом (F3–4), как и отсутствие фибро-
за у больных неалкогольной жировой болезни печени 
(НАЖБП), является важным вопросом для выяснения 
прогноза. Сывороточные маркеры были предложены как 
альтернатива биопсии. Цель: разработать новую модель 
для определения стадии фиброза на основе более эффек-
тивной комбинации серологических маркеров и сравне-
ния ее с установленными методами. Материалы и методы. 
В исследование включены 60 пациентов с НАЖБП, кото-
рые проходили обследование и лечение в отделении забо-
леваний печени и поджелудочной железы ГУ «Институт 
гастроэнтерологии НАМН Украины». Среди исследован-
ных 26 (42,3 %) мужчин и 34 (56,7 %) женщины, средний 
возраст (37,1 ± 12,4) и (44,3 ± 7,3) года соответственно. 
Всем пациентам была проведена чрескожная пункцион-
ная трепан-биопсия печени с последующим морфологи-
ческим исследованием пунктата; выполнено определение 
содержания гиалуроновой кислоты, α
2
-макроглобулина, 
аполипопротеина А1, фибронектина, гаптоглобина в сы-
воротке крови и был проведен расчет неинвазивных мар-
керов фиброза печени: AAR, APRI, FIB-4. Результаты. 
Проведенный ROC-анализ показал, что наибольшие по-
казатели площади под AUROC-кривой были для индек-
са FIB-4 для F2 — 0,72, F3 — 0,8, F4 — 0,82 при р < 0,05. 
Результаты индекса APRI были достоверно высокими для 
умеренного и выраженного фиброза (F2 — 0,74, F3 — 0,82, 
р < 0,05). А показатели AAR были достоверными толь-
ко для цирроза печени (площадь под AUROC-кривой 
0,89, р < 0,05). Установлены сильная прямая связь между 
стадией фиброза и уровнем гиалуроновой кислоты, α
2
-
макроглобулина и фибронектина (r = 0,72, 0,93 и 0,71 при 
р < 0,05 соответственно) и обратная связь умеренной силы 
между показателями аполипопротеина А1, гаптоглобина 
(r = –0,61 и –0,35 при р < 0,05). Определена прямая связь 
умеренной силы между степенью активности воспали-
тельного процесса и показателями гиалуроновой кислоты, 
α
2
-макроглобулина и фибронектина (r = 0,54, 0,67 и 0,55 
при р < 0,05) и обратная умеренная связь — аполипопро-
теина А1 и гаптоглобина (r = –0,56 и –0,33 при р < 0,05). 
Выводы. Установлено, что наибольшую диагностическую 
ценность из неинвазивных маркеров фиброза имеют пока-
затели α
2
-макроглобулина, аполипопротеина А1, гиалуро-
новой кислоты и фибронектина, для которых площадь под 
AUROC-кривой для минимального фиброза не была ниже 
0,75, а для умеренного, выраженного фиброза и цирроза 
составляла больше 0,9.
Ключевые слова: неалкогольная жировая болезнь печени; 
фиброз печени; биопсия печени; неинвазивные методы ди-
агностики
